182 related articles for article (PubMed ID: 36556957)
21. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
[TBL] [Abstract][Full Text] [Related]
22. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease.
Thimonier E; Guillaud O; Walter T; Decullier E; Vallin M; Boillot O; Dumortier J
Clin Transplant; 2014 Dec; 28(12):1339-48. PubMed ID: 25081431
[TBL] [Abstract][Full Text] [Related]
23. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience.
Ayar Y; Ersoy A; Ocakoglu G; Yildiz A; Oruc A; Soyak H; Calapkulu M; Sahin AB; Topal NB; Okeer E; Coskun B; Kaygisiz O; Kordan Y; Vuruskan H
Transplant Proc; 2017 Mar; 49(2):270-277. PubMed ID: 28219583
[TBL] [Abstract][Full Text] [Related]
24. De Novo Malignancies After Liver Transplantation With 14 Cases at a Single Center.
Liu ZN; Wang WT; Yan LN;
Transplant Proc; 2015 Oct; 47(8):2483-7. PubMed ID: 26518956
[TBL] [Abstract][Full Text] [Related]
25. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
[TBL] [Abstract][Full Text] [Related]
26. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis.
Singh S; Edakkanambeth Varayil J; Loftus EV; Talwalkar JA
Liver Transpl; 2013 Dec; 19(12):1361-9. PubMed ID: 24019127
[TBL] [Abstract][Full Text] [Related]
27. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.
Rodríguez-Perálvarez M; Tsochatzis E; Naveas MC; Pieri G; García-Caparrós C; O'Beirne J; Poyato-González A; Ferrín-Sánchez G; Montero-Álvarez JL; Patch D; Thorburn D; Briceño J; De la Mata M; Burroughs AK
J Hepatol; 2013 Dec; 59(6):1193-9. PubMed ID: 23867318
[TBL] [Abstract][Full Text] [Related]
28. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
29. Randomized Sirolimus-based Early Calcineurin Inhibitor Reduction in Liver Transplantation: Impact on Renal Function.
Buchholz BM; Ferguson JW; Schnitzbauer AA; Nightingale P; Schlitt HJ; Geissler EK; Mirza DF;
Transplantation; 2020 May; 104(5):1003-1018. PubMed ID: 31577671
[TBL] [Abstract][Full Text] [Related]
30. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
[TBL] [Abstract][Full Text] [Related]
31. Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience.
Jiménez-Romero C; Manrique A; Marqués E; Calvo J; Sesma AG; Cambra F; Abradelo M; Sterup RM; Olivares S; Justo I; Colina F; Moreno E
Hepatogastroenterology; 2011; 58(105):115-21. PubMed ID: 21510297
[TBL] [Abstract][Full Text] [Related]
32. Effect and safety of intraoperative intraperitoneal chemotherapy on patients suffering from colorectal cancer.
Shang A; Wang S; Yang Y; Li L; Zhao Z; Li D; Guo Y; Wang M
World J Surg Oncol; 2021 Mar; 19(1):84. PubMed ID: 33752702
[TBL] [Abstract][Full Text] [Related]
33. Gender, Race and Disease Etiology Predict De Novo Malignancy Risk After Liver Transplantation: Insights for Future Individualized Cancer Screening Guidance.
Bhat M; Mara K; Dierkhising R; Watt KD
Transplantation; 2019 Jan; 103(1):91-100. PubMed ID: 29377876
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
35. Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection.
Schrem H; Kurok M; Kaltenborn A; Vogel A; Walter U; Zachau L; Manns MP; Klempnauer J; Kleine M
Liver Transpl; 2013 Nov; 19(11):1252-61. PubMed ID: 24106037
[TBL] [Abstract][Full Text] [Related]
36. Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRON-study.
Schnitzbauer AA; Scherer MN; Rochon J; Sothmann J; Farkas SA; Loss M; Geissler EK; Obed A; Schlitt HJ
BMC Nephrol; 2010 Sep; 11():24. PubMed ID: 20840760
[TBL] [Abstract][Full Text] [Related]
37. Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis.
Mouchli MA; Singh S; Loftus EV; Boardman L; Talwalkar J; Rosen CB; Heimbach JK; Wiesner RH; Hasan B; Poterucha JJ; Kymberly WD
Transplantation; 2017 Aug; 101(8):1859-1866. PubMed ID: 28272287
[TBL] [Abstract][Full Text] [Related]
38. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital.
San Miguel C; Fundora Y; Triguero J; Muffak K; Villegas T; Becerra A; Garrote D; Ferrón JA
Transplant Proc; 2015 Oct; 47(8):2371-3. PubMed ID: 26518930
[TBL] [Abstract][Full Text] [Related]
39. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age.
Tjon AS; Sint Nicolaas J; Kwekkeboom J; de Man RA; Kazemier G; Tilanus HW; Hansen BE; van der Laan LJ; Tha-In T; Metselaar HJ
Liver Transpl; 2010 Jul; 16(7):837-46. PubMed ID: 20583092
[TBL] [Abstract][Full Text] [Related]
40. Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment: Results of a Pilot Study (PATRON07).
Schnitzbauer AA; Sothmann J; Baier L; Bein T; Geissler EK; Scherer MN; Schlitt HJ
Transplantation; 2015 Dec; 99(12):2565-75. PubMed ID: 26018348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
